FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954853806> ?p ?o ?g. }

• W2954853806 endingPage "CT157" @default.
• W2954853806 startingPage "CT157" @default.
• W2954853806 abstract "Abstract Background: Most patients with advanced OC relapse after initial standard platinum-based chemotherapy, and eventually the disease becomes platinum-resistant. Niraparib (ZEJULA®) was the first selective poly(ADP-ribose) polymerase inhibitor (PARPi) approved in the United States and Europe for maintenance treatment in patients with recurrent OC regardless of BRCA mutation status. Preclinical evidence suggests that niraparib activates the stimulator of interferon genes pathway to increase immune cell infiltration and synergizes with anti-PD-1 therapy. Additionally, hypoxia induces contextual synthetic lethality by impairing homologous recombination, and therefore induction of hypoxia by inhibition of angiogenesis could lead to synergy with PARPi. In the TOPACIO/KEYNOTE-162 trial, niraparib in combination with pembrolizumab has shown efficacy in recurrent, platinum-resistant OC. Niraparib in combination with the anti-angiogenic agent bevacizumab is under study for the treatment of recurrent platinum-sensitive OC (AVANOVA trial) and advanced OC following response on frontline platinum-based chemotherapy (OVARIO trial). TSR-042 is an anti-PD-1 humanized monoclonal antibody that has shown clinical activity as monotherapy in early phase trials. Cohort A of the OPAL trial will evaluate the novel triple combination of the PARPi niraparib, angiogenesis inhibitor bevacizumab, and PD-1 inhibitor TSR-042 in patients with platinum-resistant OC who are naïve to PARPi therapy. Methods: Eligible patients will have high-grade recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer of the ovary and progressed ≤6 months from completion of ≥4 cycles of platinum-based chemotherapy. Additional key eligibility criteria include 1-2 prior lines of anticancer therapy for OC, no prior therapy with an anti-PD-1 or anti-PD-L1 antibody, and no prior therapy for OC with a PARPi. Patients will receive a combination regimen of 500 mg TSR-042 on day 1 of each 3-week cycle for 4 cycles, then 1000 mg on day 1 of every other cycle beginning on cycle 5 until progression or toxicity, 15 mg/kg bevacizumab on day 1 of each 3-week cycle for up to 15 months, and niraparib 300 mg or 200 mg (for patients &lt;77 kg or platelet count &lt;150,000/µL at screening) daily until disease progression or toxicity. The primary endpoint is to evaluate treatment efficacy by confirmed objective response rate per investigator-assessed RECIST v1.1 criteria. Secondary objectives are evaluation of progression-free survival, overall survival, duration of response, and disease control rate. Exploratory objectives are to identify potential biomarkers of tumor response, including BRCA status and homologous recombination repair gene status and to evaluate the evolution of the molecular profile of the tumor and tumor microenvironment in response to treatment. Clinical trial identification: NCT03574779 Citation Format: Joyce Liu, Camille Gunderson, Andrea Wahner Hendrickson, Elena Ratner, Elisabeth Diver, John Moroney, Rebecca C. Arend, Melinda Louie-Gao, Sarah Wang, Katarina Luptakova, Gottfried E. Konecny. An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT157." @default.
• W2954853806 created "2019-07-12" @default.
• W2954853806 creator A5000378651 @default.
• W2954853806 creator A5021257078 @default.
• W2954853806 creator A5040851961 @default.
• W2954853806 creator A5041031647 @default.
• W2954853806 creator A5043625183 @default.
• W2954853806 creator A5044252805 @default.
• W2954853806 creator A5053645352 @default.
• W2954853806 creator A5060086956 @default.
• W2954853806 creator A5060953135 @default.
• W2954853806 creator A5062837404 @default.
• W2954853806 creator A5063723398 @default.
• W2954853806 date "2019-07-01" @default.
• W2954853806 modified "2023-09-25" @default.
• W2954853806 title "Abstract CT157: An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial" @default.
• W2954853806 doi "https://doi.org/10.1158/1538-7445.am2019-ct157" @default.
• W2954853806 hasPublicationYear "2019" @default.
• W2954853806 type Work @default.
• W2954853806 sameAs 2954853806 @default.
• W2954853806 citedByCount "1" @default.
• W2954853806 countsByYear W29548538062021 @default.
• W2954853806 crossrefType "journal-article" @default.
• W2954853806 hasAuthorship W2954853806A5000378651 @default.
• W2954853806 hasAuthorship W2954853806A5021257078 @default.
• W2954853806 hasAuthorship W2954853806A5040851961 @default.
• W2954853806 hasAuthorship W2954853806A5041031647 @default.
• W2954853806 hasAuthorship W2954853806A5043625183 @default.
• W2954853806 hasAuthorship W2954853806A5044252805 @default.
• W2954853806 hasAuthorship W2954853806A5053645352 @default.
• W2954853806 hasAuthorship W2954853806A5060086956 @default.
• W2954853806 hasAuthorship W2954853806A5060953135 @default.
• W2954853806 hasAuthorship W2954853806A5062837404 @default.
• W2954853806 hasAuthorship W2954853806A5063723398 @default.
• W2954853806 hasConcept C104317684 @default.
• W2954853806 hasConcept C121608353 @default.
• W2954853806 hasConcept C126322002 @default.
• W2954853806 hasConcept C143998085 @default.
• W2954853806 hasConcept C182979987 @default.
• W2954853806 hasConcept C2776694085 @default.
• W2954853806 hasConcept C2777802072 @default.
• W2954853806 hasConcept C2778822529 @default.
• W2954853806 hasConcept C2779962180 @default.
• W2954853806 hasConcept C2780194787 @default.
• W2954853806 hasConcept C2780427987 @default.
• W2954853806 hasConcept C502942594 @default.
• W2954853806 hasConcept C55493867 @default.
• W2954853806 hasConcept C71924100 @default.
• W2954853806 hasConcept C82381507 @default.
• W2954853806 hasConcept C86803240 @default.
• W2954853806 hasConceptScore W2954853806C104317684 @default.
• W2954853806 hasConceptScore W2954853806C121608353 @default.
• W2954853806 hasConceptScore W2954853806C126322002 @default.
• W2954853806 hasConceptScore W2954853806C143998085 @default.
• W2954853806 hasConceptScore W2954853806C182979987 @default.
• W2954853806 hasConceptScore W2954853806C2776694085 @default.
• W2954853806 hasConceptScore W2954853806C2777802072 @default.
• W2954853806 hasConceptScore W2954853806C2778822529 @default.
• W2954853806 hasConceptScore W2954853806C2779962180 @default.
• W2954853806 hasConceptScore W2954853806C2780194787 @default.
• W2954853806 hasConceptScore W2954853806C2780427987 @default.
• W2954853806 hasConceptScore W2954853806C502942594 @default.
• W2954853806 hasConceptScore W2954853806C55493867 @default.
• W2954853806 hasConceptScore W2954853806C71924100 @default.
• W2954853806 hasConceptScore W2954853806C82381507 @default.
• W2954853806 hasConceptScore W2954853806C86803240 @default.
• W2954853806 hasIssue "13_Supplement" @default.
• W2954853806 hasLocation W29548538061 @default.
• W2954853806 hasOpenAccess W2954853806 @default.
• W2954853806 hasPrimaryLocation W29548538061 @default.
• W2954853806 hasRelatedWork W1520606981 @default.
• W2954853806 hasRelatedWork W2147619880 @default.
• W2954853806 hasRelatedWork W2150161065 @default.
• W2954853806 hasRelatedWork W2950446512 @default.
• W2954853806 hasRelatedWork W3015072749 @default.
• W2954853806 hasRelatedWork W3040343436 @default.
• W2954853806 hasRelatedWork W3090114554 @default.
• W2954853806 hasRelatedWork W3154406130 @default.
• W2954853806 hasRelatedWork W3204368990 @default.
• W2954853806 hasRelatedWork W4283025800 @default.
• W2954853806 hasVolume "79" @default.
• W2954853806 isParatext "false" @default.
• W2954853806 isRetracted "false" @default.
• W2954853806 magId "2954853806" @default.
• W2954853806 workType "article" @default.